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Apelin is a bioactive peptide involved in the control of energy metabolism. In the hypothalamus, chronic 
exposure to high levels of apelin is associated with an increase in hepatic glucose production, and then 
contributes to the onset of type 2 diabetes. However, the molecular mechanisms behind deleterious 
effects of chronic apelin in the brain and consequences on energy expenditure and thermogenesis 
are currently unknown. We aimed to evaluate the effects of chronic intracerebroventricular (icv) 
infusion of apelin in normal mice on hypothalamic inflammatory gene expression, energy expenditure, 
thermogenesis and brown adipose tissue functions. We have shown that chronic icv infusion of apelin 
increases the expression of pro-inflammatory factors in the hypothalamus associated with an increase 
in plasma interleukin-1 beta. In parallel, mice infused with icv apelin exhibit a significant lower energy 
expenditure coupled to a decrease in PGC1alpha, PRDM16 and UCP1 expression in brown adipose 
tissue which could explain the alteration of thermogenesis in these mice. These data provide compelling 
evidence that central apelin contributes to the development of type 2 diabetes by altering energy 
expenditure, thermogenesis and fat browning.
Obesity and metabolic diseases are becoming worldwide epidemics, and are considered as public health issue. 
Obesity is associated with low-grade chronic inflammation that contributes to the development of insulin resist-
ance, type 2 diabetes (T2D) and cardiovascular diseases1. However, the mechanisms underlying diabetes, obesity, 
fat mass development and the onset of inflammation have not been fully defined. There are several potential 
mechanisms through which molecular signals have been linked to inflammatory signaling, such as mitochondrial 
dysfunction, oxidative stress and endoplasmic reticulum (ER) stress2. The brain, and more precisely the hypothal-
amus, has been shown to be a primary site for body dysfunction in metabolic syndrome3. Consequently, altered 
hypothalamic responses have been associated with dysfunction of metabolic and energy homeostasis, including 
food intake, energy expenditure4, nutrient sensing and glucose metabolism3. Moreover, the hypothalamus is the 
target of numerous pro-inflammatory stimuli5, leading to diabetes features6–8.
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Apelin is a bioactive peptide identified in 1998 as the endogenous ligand of the orphan G-protein coupled receptor 
APJ9. APJ is expressed in many peripheral tissues, as well as in different brain areas including the hypothalamus10. In 
periphery, intravenous injection of apelin improves insulin sensitivity in normal and obese/diabetic mice11. In the brain, 
apelin is now considered as a new hypothalamic actor that might contribute to the control of glucose metabolism12–14.
Evidence shows a controversial role of apelin in the regulation of food intake15–17, but a consensus exists 
regarding its impact in the control of glucose homeostasis12,13. Although low quantity of central apelin improves 
fed glycaemia in normal mice, a pathophysiological increase in apelin expression in the hypothalamus generates 
fasting hyperglycaemia13. More precisely, acute and chronic intracerebroventricular (icv) infusions of apelin, that 
mimic the levels of apelin present in the hypothalamus of obese/diabetic mice18, induce T2D characteristics in 
normal mice, including fasting hyperglycaemia, hyperinsulinaemia and insulin intolerance13.
Adipose tissue is an important regulator of energy balance which plays a complex, but a key role in the con-
trol of metabolic functions. Although white adipose tissue provides lipids as energetic substrates during fasting 
periods, brown adipose tissue (BAT) and beiging/browning processes contribute to dissipate the chemical energy 
stored as heat to preserve core temperature during hypothermia and to counteract obesity19. BAT adipocytes 
contain a high number of mitochondria, which are characterized by the presence of uncoupling protein-1 (UCP1) 
in the inner mitochondrial membrane. After its activation, this protein uncouples the mitochondrial respiration 
from ATP synthesis that results in heat production corresponding to the “non-shivering thermogenesis”.
The role of BAT activation appears to be broader than solely the promotion of negative energy balance. Indeed, 
BAT is now viewed as an organ that can be targeted to exert anti-diabetic effects associated with improvements of 
dyslipidemia and insulin secretion as well as decrease insulin resistance in T2D20–22. Finally, the central nervous sys-
tem controls thermogenesis via sympathetic nervous system23,24. More precisely, hypothalamic proopiomelanocortin 
(POMC) neurons are now considered as major type of neurons implicated in the control of energy expenditure25,26.
Thus, the present work aims to: 1) determine whether chronic icv apelin infusion in mice induces hypotha-
lamic and/or systemic inflammation; and 2) investigate the peripheral consequences of this chronic treatment on 
whole-body energy expenditure, which is profoundly altered during insulin resistance4,27; and on thermogenesis 
BAT function which is under the control of hypothalamus in normal and pathological conditions28,29.
Results
Chronic icv apelin increases the expression of hypothalamic pro-inflammatory markers. We have 
previously shown that over-expression of apelin in the hypothalamus via lentiviral approaches provokes a T2D phe-
notype in normal mice by increasing hepatic gluconeogenesis and glycogenolysis12,30. To further explore the impact 
of chronic exposure of apelin in the brain, we developed a mice model chronically perfused with apelin in lateral 
ventricle. We measured the expression and activity of a hepatic enzyme implicated in gluconeogenesis and glycog-
enolysis. In accordance with our previous study12, we demonstrated an increase in Hepatic glucose 6-phosphatase 
(G6Pase) mRNA expression (Suppl. Fig. 1a) and activity (Suppl. Fig. 1a) in icv apelin treated mice that could con-
tribute to the fasting hyperglycemia and therefore the T2D phenotype observed in this experimental model31. Again, 
we found that chronic apelin is associated with an increase in plasma noradrenalin (Suppl. Fig. 1b), but not adrenalin 
(Suppl. Fig. 1b), confirming the over-activation of sympathetic tone as previously described12. Thus we conclude that 
the present icv model is comparable to our previous model of chronic expression of apelin.
Given that, first, a positive correlation exists between apelin and inflammation during metabolic diseases32 
and, second, an inflammatory induction was demonstrated in microglial cells culture in response to apelin33, 
we have decide to measure the variations of specific pro-inflammatory markers expressed in the entire hypo-
thalamus. We found that chronic icv treatment significantly increases Interleukin-1 beta (Il1beta) (Fig. 1a) and 
Inducible Nitric Oxide Synthase (Inos) (Fig. 1c) mRNA expression, while a trend is noted for Tumor Necrosis Factor 
alpha (Tnfalpha) (p = 0.0807, Fig. 1b), thereby suggesting an increased inflammation in this model. Changes at 
the mRNA levels were associated with an increase in hypothalamic iNOS protein expression, but not for IL1beta 
and TNFalpha (Fig. 1d–f). These effects are specific to the hypothalamus since no significant variations are 
observed for the three markers in the brain stem (Suppl. Fig. 2a–c) or cortex (Suppl. Fig. 2d–f). Moreover, this 
hypothalamic inflammation is associated with an increase in plasma IL1beta (Fig. 1g) but not TNFalpha (Fig. 1h). 
The plasma iNOS expression was not detected in our samples (Fig. 1i).
Chronic icv apelin does not modify body weight and food intake, but stimulates hypothalamic 
POMC neurons. We have previously found that chronic perfusion of icv apelin did not modify body weight 
and food intake31. Here we show that tissue weights are not modified by icv apelin treatment (Fig. 2a) thereby 
supporting the absence of body weight gain. Plasma triglycerides (TG) and free fatty acids (FFA) are not affected 
(Fig. 2b). The absence of effect on food intake is correlated with the lack of variations of neuropeptide Y (NPY) 
mRNA and proopiomelanocortin (POMC) expressions in the hypothalamus between control and apelin treated 
mice (Fig. 2c,d). As APJ receptor is strongly expressed on POMC neurons compared to NPY neurons18, we 
have measured the impact of apelin on these neurons by electrophysiological recordings in brain slices from 
POMC-eGFP mice. Apelin (20 nM) increases action potential frequency in ~50% of POMC-expressing neurons 
(n = 9/19) by 57.9 ± 11.3% (control: 2.11 ± 0.44 vs. apelin: 3.26 ± 0.57 Hz; n = 9; p < 0.05) (Fig. 2e). In general, 
POMC neurons do not return to basal firing rates until at least 10 minutes after peptide application. This sustained 
effect is consistent with the effect of apelin observed on vasopressin neurons23.
Chronic icv apelin decreases energy expenditure, without modification of ambulatory activity. 
We previously demonstrated that hypothalamic apelin was involved in the onset of insulin resistance and T2D31, 
which are known to be associated with altered energy expenditure4. To explore this hypothesis, we measured 
the effects of chronic icv apelin on energy expenditure by indirect calorimetry. Apelin treatment do not modify 
the ambulatory activity during the dark and light periods (Fig. 3a–c). Apelin-treated mice showed decreased 
www.nature.com/scientificreports/
3Scientific RepoRts | 6:31849 | DOI: 10.1038/srep31849
energy expenditure, oxygen consumption (VO2) and carbon dioxide production (VCO2) (Fig. 4a–c) during the 
dark period (i.e., during the feeding period of the mice)31. This effect is associated with a slight but significantly 
reduced respiratory quotient during the light phase (Fig. 4d).
Chronic icv apelin alters thermogenesis and BAT function. BAT contains a high density of mito-
chondria with high amounts of UCP1 allowing the uncoupling of fatty acid oxidation from ATP production to 
generate heat34.
We found that chronic icv apelin perfusion decreased the expression of Peroxisome proliferator-activated receptor 
1 alpha (Pgc1alpha) mRNA in BAT (Fig. 5a) which is a key regulator of mitochondrial biogenesis35, and PR 
domain containing 16 (Prdm16) mRNA (Fig. 5b), a key transcriptional cofactor involved in BAT differentiation36. 
This result suggests that chronic icv apelin perfusion decreases mitochondrial biogenesis and reduces BAT activ-
ity. In addition, UCP1 protein level is significantly decreased in BAT in response to chronic icv apelin perfusion 
(Fig. 5c), validating a disruption of its function. This was associated with a decrease in body temperature at room 
temperature (Fig. 5d) and an altered response to cold exposure (Fig. 5e) in mice perfused with chronic icv ape-
lin, thereby contributing to explain the decreased energy expenditure upon apelin treatment. In the BAT, genes 
encoding lipids or glucose transports markers are not modified between the 2 groups of mice (Suppl. Fig. 3a–f).
Figure 1. Chronic icv apelin increases the expression of hypothalamic and plasma pro-inflammatory 
markers. Effect of chronic apelin treatment (Apelin) versus chronic aCSF treatment (Control) on hypothalamic 
(a) Il1beta (b) Tnfalpha and on (c) Inos mRNA expression. Effect of chronic apelin treatment (Apelin) versus 
chronic aCSF treatment (Control) on IL1beta (d), TNFalpha (e) and iNOS (f) hypothalamic levels. Effect of 
chronic apelin treatment (Apelin) versus chronic aCSF treatment (Control) on IL1beta (g), TNFalpha (h) and 
iNOS (i) plasma levels. Experiments were performed with a set of 5–7 9 mice in each group. * p < 0.05,  
* * p < 0.01. N.D: Not Determined.
www.nature.com/scientificreports/
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Discussion
In the present study, we have demonstrated that central chronic perfusion of apelin, at a dose known to induce 
insulin resistance31, increases hypothalamic and plasma inflammation, decreases energy expenditure and ther-
mogenesis associated with an alteration of BAT function.
The role of apelin as anti-inflammatory marker in peripheral tissues is still a matter of debate. For example, 
data from literature suggest that apelin 1) has an anti-inflammatory role in heart37, 2) prevents UVB-induced 
inflammation38 or 3) inhibits macrophages inflammation in aorta39. Conversely, we have previously found a 
positive correlation between inflammation and apelin/APJ expression in intestinal and adipose tissue of obese/
Figure 2. Apelin depolarizes POMC neurons in the hypothalamus without effect on food intake and tissue 
weight. Effect of chronic apelin treatment (Apelin) versus chronic aCSF treatment (Control) (a) on tissues 
weight (SC: subcutaneous adipose tissue, PG: perigonadal adipose tissue, Mes: mesenteric adipose tissue, BAT: 
brown adipose tissue, VL: vastus lateralis (muscle); HL: muscle; EDL: extensor digitorum longus (muscle)); 
(b) on triglycerides (TG) and free fatty acids (FFA) plasma levels; (c) on hypothalamic Npy mRNA expression 
and; (d) on hypothalamic Pomc mRNA expression. (e) (Left panel) Representative cell-attached recording of 
a POMC-GFP neuron activated by apelin (thick black bar under the trace). Panels below the trace represent 
enlarged 60 seconds recording periods with average action potential frequency before, during and after apelin 
bath application. (Right panel) Quantification of action potential (AP) frequency of POMC before (control; over 
the last 60 s before apelin application), during (apelin, over the last 60 seconds of apelin application) and after 
(reversal, over 60 seconds, 5 minutes after apelin application) apelin application. Experiments were performed 
with a set of 6–9 mice in each group. * * p < 0.01; * p < 0.05 vs. control.
www.nature.com/scientificreports/
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diabetic mice40. In the brain, we have demonstrated that high levels of apelin (mimicking the quantity of apelin 
present in the hypothalamus of obese/diabetic mice)18, generate hypothalamic inflammatory state with the induc-
tion of Il1beta and Tnfalpha expression12. Along the same line, Chen et al. have recently described that apelin 
induces inflammatory signalling pathways in the BV2 microglial cell line33. In the present study, brain Il1beta and 
Inos mRNA levels were increased in apelin-treated mice, reinforcing the inflammatory role of apelin in the hypo-
thalamus. In parallel, iNOS protein expression, but not IL1beta, is significantly increased in the hypothalamus of 
apelin-treated mice. These data are in accordance with the variation of mRNA expression except for IL1b. This 
last result could be justify by the existence of a diurnal rhythm of IL1b expression in specific brain regions includ-
ing the hypothalamus41. In addition, microglial inflammatory responses are controlled by an intrinsic circadian 
clock including TNFa, IL1b and IL642, thereby suggesting that time is a factor to consider when investigating 
inflammatory interventions on the brain42. Whether this phenomenon occur in the present experimental setting 
remain to be investigated.
We have previously demonstrated that chronic icv apelin infusion triggered the onset of glucose homeosta-
sis disorders, e.g., glucose intolerance and insulin resistance31. However, altered regulation of energy expend-
iture is among the key features associated with obesity and T2D. A plethora of targets have been identified as 
major regulators of energy balance, playing roles in energy intake and/or expenditure43,44. Here, we have dis-
covered that apelin chronically perfused in the brain reduced energy expenditure during the feeding period. 
Interestingly, apelin and its receptor are expressed in hypothalamic POMC neurons and control the release of 
alpha-melanocyte-stimulating hormone (alphaMSH)18. Our data, combined with the literature, strongly suggest 
that apelin controls energy homeostasis by different mechanisms. Therefore, we speculate that the altered energy 
expenditure observed during obesity might occur via apelin-dependent mechanisms on POMC neurons since 
we demonstrate that apelin activates these neurons in the arcuate nucleus. The absence of effect on food intake 
despite the modification of POMC activity in response to apelin fits with the demonstration that hypothalamic 
POMC neurons present a functional heterogeneity45. In fact, data from literature support the hypothesis that 
distinct populations of POMC neurons are implicated in the control of food intake and energy metabolism45. 
Activation of POMC neurons is usually associated with an increase in energy expenditure. Conversely, our data 
show a decrease in energy expenditure linked to a POMC neurons depolarization. In the hypothalamus, POMC 
Figure 3. Chronic icv apelin does not modulate ambulatory activity. Effect of chronic apelin treatment 
(Apelin) versus chronic aCSF treatment (Control) (a) on global ambulatory activity; (b) on ambulatory activity 
during the light period; (c) on ambulatory activity during the dark period. Experiments were performed with a 
set of 5–6 mice in each group.
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neurons are considered as target of apelin actions. Apelin is also expressed on POMC neurons, and quantitative 
analysis demonstrated that 89% of apelin neurons contained POMC, whereas less than 10% contained NPY. 
However, numerous NPY nerve fibers are detected close to apelin neuronal cell bodies implying potential con-
trol of NPY on POMC/Apelin neurons activity13. We have shown that apelin released from POMC neurons may 
stimulate α -MSH release in an autocrine manner18. Similar effect could be proposed on NPY neurons. Another 
explanation may be that apelin acts on glutamatergic neurons located on paraventricular nucleus of the hypothal-
amus. Thus, stimulation of these neurons by apelin generates an activation of the sympathetic nervous system46 
which could explain the phenotype of chronic icv apelin treated mice. In fact, the role of hypothalamic apelin in 
the control of glucose metabolism remains to be unraveled, and is complex. Again, data from the literature show 
Figure 4. Chronic icv apelin decreases energy expenditure. Effect of chronic apelin treatment (Apelin) versus 
chronic aCSF treatment (Control) (a) on energy expenditure with a focus during dark and light period; (b) on 
VO2 with a focus during dark and light period; (c) on VCO2 with a focus during dark and light period and;  
(d) on Respiratory Quotient (RQ) with a focus during dark and light period. Experiments were performed with 
a set of 5–6 mice in each group. * p < 0.05, * * p < 0.01.
www.nature.com/scientificreports/
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that stimulation of MC4R in the brain (i.e., the α -MSH receptor) stimulates the activation of sympathetic nervous 
system47. This is similar to that we have observed in our experimental model12 thereby explaining the onset of 
the diabetic phenotype (i.e., hyperglycemia and decrease of energy expenditure) in chronic icv apelin perfused 
mice. To conclude, we cannot rule out the possible presence of APJ receptor on specific subpopulations of POMC 
neurons implicated in the control of glucose metabolism. Future experiments will be performed to unravel this 
complex role of central apelin on energy homeostasis.
We do not observe significant changes in body weight and fat mass development after two-weeks of apelin 
infusion into the brain, whereas energy expenditure was significantly decreased. We cannot exclude that a longer 
period of treatment could significantly affect body weight and fat storage, we have found no significant variation 
Figure 5. Chronic icv apelin mice present an alteration of thermogenesis. Effects of chronic apelin treatment 
(Apelin) versus chronic aCSF treatment (Control) (a) on BAT Pgc1alpha mRNA expression; (b) on BAT Prdm16 
mRNA expression; (c) on BAT UCP1 protein level; (d) on body temperature at room temperature and; (e) on 
body temperature at 4 °C. Experiments were performed with a set of 4–7 mice in each group. * p < 0.05,  
* * p < 0.01.
www.nature.com/scientificreports/
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of body weight after one month of icv apelin perfusion (personal communication). Another potential speculation 
is that chronic apelin treatment slightly but significantly reduced the respiratory quotient during the light phase. 
This finding might support a trend to shift towards lipid oxidation instead of carbohydrate utilization as previ-
ously described with peripheral long term apelin treatment48. Thus, this may contribute to the lack of increase in 
body weight and fat deposition during the treatment period, compensating the reduced energy expenditure at the 
onset of the pathology. In fact, we have previously published that chronic icv apelin increases hepatic neogluco-
genesis12 hence contributing to the development of the diabetic phenotype in mice. Recently, Perry et al.49 have 
demonstrated that the increase in hepatic neoglucogenesis observed in obese/diabetic mice is due to an elevation 
in hepatic acetyl coA which results from the increased rates of white adipose tissue lipolysis (i.e., oxidation). 
Taken together, our data support the hypothesis that, in spite of a decrease in energy expenditure associated with 
BAT dysfunction, the increase in hepatic neoglucogenesis observed in our experimental model favours the slight 
increase in lipid oxidation.
T2D is associated with a decrease in energy expenditure and alteration of metabolic tissues functions, leading 
to an altered nutrients utilisation and insulin resistance. We have previously described that acutely mimicking the 
levels of apelin measured in the brain of obese and diabetic mice increase hepatic glucose production during the 
fasted period, a feature of T2D12. In this study, we found an increase in G6Pase mRNA expression and enzymatic 
activity, confirming power full brain to liver axis, and that the liver is a target of high levels of apelin. In addition 
to the liver, we demonstrated in this study that BAT function and thermogenesis were also modified in response 
to chronic icv apelin. We found that the pre-diabetic phenotype induced by icv apelin treatment was associated 
with a decrease in Pgc1alpha and Prdm16 mRNA expression and a decrease in UCP1 proteins level in BAT. These 
data confirm the deleterious effect of chronic central apelin injection on energy metabolism12,13 as opposed to its 
peripheral beneficial effects on insulin sensitivity11. Here, we discovered that central apelin exerts inverse effect 
on BAT function as opposed to its direct effects on the brown adipogenic capacity and browning28. This last result 
fits with the concept that we have previously highlighted demonstrating that over-expression of apelin in the brain 
participates to the establishment of T2D30,50,51. Therefore, we speculate that the decrease in energy expenditure 
observed in these mice might be explained by the reduced expression of key factors characterizing BAT activity. 
Indeed, UCP1 is generally recognized as the defining marker of brown fat and interacts strongly with PGC1alpha, 
the master regulator of UCP1-mediated thermogenesis in BAT52,53. Moreover, numerous data from the literature 
have demonstrated that PGC1alpha acts as a crucial factor in the control of mitochondrial biogenesis and energy 
status54. Thus, it has been considered as a potential therapeutic target for treating mitochondrial dysfunction asso-
ciated with insulin resistance55. Although Pgc1a and Prdm16 mRNA expression have been previously associated 
with mitochondrial biogenesis (i.e., real quantification), our data strongly suggest this association but does not 
show this link in our set of data. In addition, PRDM16 was considered as an activator of brown fat cell identity, at 
least in part by stimulating PGC1alpha expression and activity36. Taken together, these molecular modifications 
involved in the key thermogenic role of BAT are strongly linked to the decrease in rectal temperature, which 
mirror basal metabolic rate, but also with the lower energy expenditure observed in response to chronic icv ape-
lin in mice. Here, we discovered that central apelin significantly increases the level of plasma cytokine IL1beta. 
Recently, Goto et al. have demonstrated that IL1beta suppresses cold-induced thermogenesis in adipocytes56 
which brings a potential molecular explanation to decipher the metabolic phenotype of our central apelin-treated 
mice. Furthermore, a possible link between plasma IL1beta and thermogenesis could be UCP1 since IL1beta is 
able to decrease UCP1 expression in adipocytes56 similar to that observed in our study.
In conclusion, the central regulation of energy metabolism has become a hot topic in recent years, and it was 
demonstrated that the hypothalamic structures are largely implicated. Taken together, we found that increased 
brain apelin levels, induce a local inflammatory state in the hypothalamus, but is also correlated with an increase 
in plasma IL1beta levels. This is associated with a reduced energy expenditure likely paralleled by a reduced BAT 
activity and thermogenesis. Thus, data from the literature and from the present study suggest that hypothalamic 
inflammation generates a pre-T2D state via multiple peripheral organ dysfunctions, including BAT.
Materials and Methods
Animals. This study was performed in accordance with appropriate guidelines from the Guide for the Care 
and Use of Laboratory Animals of the European Council. All experimental protocols were approved by the 
Animal Care and Ethics Committee of US006/CREFE (CEEA-122) with permit N° C3155508. C57Bl6/J mice 
were obtained from Charles River Laboratory (l’Arbresle, France). The mice were housed in Specific Pathogen 
Free zone in a constant temperature (20–22 °C) and humidity (50–60%) animal room with a 12/12 h light/
dark cycle (lights off at 7:00 am) and with free access to food and water over the 24 h period. All injections and 
experiments were performed in 13- to 15-week-old males. Different sets of mice were used for the experiments 
described below.
Surgical procedures. For in vivo chronic infusions, an indwelling icv catheter (Alzet Brain Perfusion Kit 
3, 1–3 mm, Charles River, L’Arbresle, France, − 1 mm lateral, − 0.2 mm anteroposterior from the bregma and 
− 1.7 mm deep) was implanted in anesthetised mice with isoflurane (Abbott, Rungis, France). The icv catheter was 
connected to an osmotic mini-pump (Model 2004, Alzet; Cupertino, CA) as previously described4,31.
Chronic infusion of apelin. Briefly, an osmotic mini-pump system connected to the lateral ventricle deliv-
ered either aCSF or apelin-13 (20 nM) over 2 weeks, at a rate of 0.25 μ l/h as previously used31. At this dose and 
in this experimental model, icv apelin provoked fasting hyperglycaemia and hyperinsulinaemia, glucose intoler-
ance, insulin intolerance and insulin resistance31. It is worth noting that the stability of apelin and the duration of 
the treatment were compatible with the stability of the molecule in such experimental conditions, as previously 
described by several groups31,46. Moreover, we tested the apelin from the pumps after the 2 weeks of treatment, 
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and was still active. To demonstrate this, apelin from the pumps harvested at the end of the experiments was 
directly injected icv in another set of mice. Here, we found that acute icv apelin has conserved its central action 
and generated a fasting hyperglycemia (data not shown) as previously described31.
The mice were housed individually during the 2 weeks and the temperature was taken in the end of this 
chronic infusion.
Dissection
The mice were fasted for 6 h and sacrificed. BAT, hypothalamus and liver were removed, frozen and powdered 
in liquid nitrogen and were kept at − 80 °C until the experiments. Plasmas were also taken from mice for ELISA 
assays.
Plasma assays. Plasma IL1beta (Sigma Aldrich, MO, USA), TNFalpha (Invitrogen, MD, USA) and iNOS 
(LSBio, WA, USA) levels were measured with ELISA kits using manufacturer’s instructions. Catecholamine con-
tent of the plasma was determined as previously described in details using high-performance liquid chromatog-
raphy coupled with electrochemical detection after alumina extraction12. Plasma TG and FFA were measured as 
previously described57.
RT-qPCR. Total RNA from tissues were prepared using the TriPure reagent (Roche, Basel, Switzerland) as pre-
viously described57,58. Primer sequences for the targeted mouse genes are presented in Table 1. cDNA were pre-
pared by reverse transcription of 1 μ g of total RNA, using a Reverse Transcription System kit (Promega, Leiden, 
the Netherlands). Real-time PCR was performed with the StepOnePlusTM real-time PCR system and software 
(Applied Biosystems, Den Ijssel, the Netherlands) using Mesa Fast qPCRTM (Eurogentec, Seraing, Belgium) for 
detection, according to the manufacturers’ instructions. Beta2microglobulin was chosen as housekeeping gene 
in the liver and BAT; Rpl19 was chosen as housekeeping gene in the brain since Rpl19 expression did not varied 
during rodent brain development59. All of the tissues were run in duplicate on a single 96-well reaction plate 
(MicroAmp Optical, Applied Biosystems), and data were analysed according to the 2 −ΔΔCT method. The identity 
and purity of the amplified product were assessed by analysis of the melting curve, performed at the end of ampli-
fication. Primer sequences for the targeted mouse genes are presented on Table 1.
Enzymatic activity. Hepatic glucose-6-phosphatase activity was determined as previously described in 
details12.
Indirect calorimetric and ambulatory activity. Twenty-four-hour energy expenditure was measured 
by indirect calorimetry (Oxylet; Panlab Bioseb, Chaville, France) during week 2 of the treatment, as previ-
ously described4. Oxygen consumption (VO2), carbon dioxide production (VCO2), Respiratory quotient (RQ) 
(calculated according to the following formula: VCO2/VO2), energy expenditure (calculated according to the 
following formula: 1.44xVO2x[3.815 + 1.232 x RQ], and ambulatory activity were measured in control and 
apelin-treated mice. Oxygen consumption and carbon dioxide production were measured over a 24-h period. 
Target genes
Primer sequence 5′ to 3′ 
Sense Antisense
Beta2microglobulin CACTGACCGGCCTGTATGC GGGTGGCGTGAGTATACTTGAATT
Cd36 GGACATACTTAGATGTGGAACCCATA TGTTGACCTGCAGTCGTTTTG
Fabp4 TGTGGGAACCTGGAAGCTTGTC TCTGACCGGATGGTGACCAAA
Fatp1 GACAAGCTGGATCAGGCAAGC AGTGAGGCCACAGAGGCTGTT
Fiaf CAATGCCAAATTGCTCCAATT TGGCCGTGGGCTCAGT
Glut1 GGTGTGCAGCAGCCTGTGT CACAGTGAAGGCCGTGTTGA
Glut4 CCGGATTCCATCCCACAAG CATGCCACCCACAGAGAAGA
G6pase ACGTATGGATTCCGGTGTTTG CAGCTGCACAGCCCAGAA
Inos CACCTTGGACTTCACCCAGT ACCACTCGTACTTGGGATGT
Il1beta CAACCAACAAGTGATATTCTCGATG GATCCACACTCTCCAGCTGCA
Npy CAGAAAACGCCCCCAGAAC CGGGAGAACAAGTTTCATTTCC
Pgc1alpha AAAGGATGCGCTCTCGTTCA GGAATATGGTGATCGGGAACA
Pomc AGGCCTGACACGTGGAAGAT AGCAGGAGGGCCAGCAA
Prdm16 CAGCACGGTGAAGCCATTC GCGTGCATCCGCTTGTG
Rpl19 GAAGGTCAAAGGGAATGTGTTCA CCTTGTCTGCCTTCAGCTTGT
Tnfalpha TGGGACAGTGACCTGGACTGT TTCGGAAAGCCCATTTGAGT
Table 1.  Sequence of the oligonucleotide primer sets used in RT-PCR analysis. CD36 (cluster of 
differenciation 36); Fabp4 (fatty acid-binding protein 4); Fatp1 (fatty acid transport protein 1); Fiaf (fasting-
induced adipose factor); Glut1 (glucose transporter 1); Glut4 (glucose transporter 4); G6pase (glucose-6-
phosphatase); Inos (inducible nitric oxide synthase); Il1beta (interleukin 1 beta); Npy (neuropeptide Y); 
Pgc1alpha (peroxisome proliferator-activated receptor 1 alpha); Pomc (pro-opiomelanocortin); Prdm16  
(PR domain containing 16); Rpl19 (60S ribosomal protein L19); Tnfalpha (tumour necrosis factor alpha).
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The ambulatory activities of the mice were monitored using an infrared photocell beam interruption method 
(Sedacom; Panlab-Bioseb). At the end of the protocol, the mice were sacrificed, and peripheral tissues were 
weighed.
Body temperature. Body temperature was measured at week 2 during the fed period using a thermometer 
for small animals (Thermometer TK 98802; Bioseb) and after one hour at 4 °C, as previously described4.
Western Blot. BAT tissues were homogenized in a buffer containing 50 mmol/L HEPES, pH 7.4, 2 mmol/L 
EDTA, 150 mmol/L NaCl, 30 mmol/L NaPO4, 10 mmol/L NaF, 1% Triton X-100, 10 mL/mL protease inhibitor 
(Sigma-Aldrich), 10 mL/mL phosphatase I inhibitor (Sigma-Aldrich), 10 mL/mL phosphatase II inhibitor 
(Sigma-Aldrich), and 1.5 mg/mL benzamidine HCl. Tissue homogenates were centrifuged for 25 min at 
15.000 g, and supernatants were stored at − 80 °C. Solubilized proteins from muscle tissue were run on a 4–20% 
Criterion SFX Tris-HCl (Bio-Rad, Hercules, CA), transferred onto nitrocellulose membrane (Hybond ECL, 
GE Healthcare, Buckingamshire, UK), and incubated with the primary antibodies for UCP1 (Abcam #10983; 
1/3000). Subsequently, immunoreactive proteins were determined by enhanced chemiluminescence reagent 
(Clarity Western ECL (Biorad) and visualized by exposure to CCD Imaging Chemidoc MP (Biorad, Hercules, 
CA). Volume density was analyzed for each band and normalized to total transferred proteins determined by 
stain free.
Electrophysiology. Brain slices (250 μ m) were prepared from adult POMC-eGFP mice (6–8 weeks old; 
POMC-EGFP1Low/J, The Jackson Laboratory) as previously described60. Slices were incubated at room tem-
perature, in oxygenated extracellular medium containing (in mM): 118 NaCl, 3 KCl, 1 MgCl2, 25 NaHCO3, 1.2 
NaH2PO4, 1.5 CaCl2, 5 Hepes, 2.5 D-glucose (osmolarity adjusted to 310 mOsM with sucrose, pH 7.3) for a 
recovery period (at least 60 minutes). Once in the recording chamber, slices were perfused at 2–3 ml/min with 
the same extracellular medium. Slices were observed with a Nikon microscope (EF600) outfitted for fluorescence 
(fluorescein filter) and IR-DIC videomicroscopy. Viable arcuate nucleus POMC neurons were visualized using a 
X40 water immersion objective (Nikon) with a fluorescence video camera (Nikon). Borosilicate pipettes (4–6 MΩ; 
1.5 mm OD, Sutter Instrument) were filled with filtered extracellular medium. Cell-attached recordings were 
performed using a Multiclamp 700B amplifier, digitized using the Digidata 1440A interface and acquired at 3 kHz 
using pClamp 10.3 software (Axon Instruments). Pipettes and cell capacitances were fully compensated. After 
a stable baseline was established, apelin (20 nM of [Pyr]apelin-13, Bachem) was perfused for 4–5 minutes. This 
dose of apelin (20 nM) corresponds to the quantity of apelin found in a half hypothalamus of mice31. Addition 
of this dose of apelin could increase the level of apelin in the hypothalamus by about 1.5 fold, thereby mimiking 
the quantity of hypothalamic apelin observed in obese/diabetic mice31. The firing activity was measured over the 
last minute of the apelin perfusion, 10 minutes after the perfusion and compared with the firing rate measured 
1 minute before the perfusion.
Statistical analysis. The data are expressed as the means ± SEMs. Differences between the two groups were 
assessed by Student’s unpaired t test or one way ANOVA, followed by post-hoc Bonferroni-test, as appropriate. 
The data were analysed using GraphPad Prism software, version 5.00 for Windows (GraphPad Software, San 
Diego, CA, USA). The results were considered statistically significant at p < 0.05.
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